Discussion
NewAmsterdam Pharma has dosed the first participant in a large mid-stage clinical trial assessing the safety and effectiveness of its cholesterol-lowering treatment candidate obicetrapib as a potential aid for people with preclinical Alzheimer’s disease. The biopharmaceutical company is developing the oral med for individuals at risk of…